The Cellsearch(R) Circulating Tumor Cells, Colon test contains 1 test with 1 biomarker.
This test can detect the presence of circulating tumor cells (CTC) in the peripheral blood of patients with metastatic breast cancer, colorectal or prostate cancer in patients. A count of 5 CTC or more in breast and prostate cancers and 3 CTC or more in colon cancer in 7.5 mL of blood is predictive of shorter progression free survival and overall survival. Physicians can draw samples prior to a new line of therapy for baseline prediction. Physicians can also draw samples at the first follow-up visit for evaluating response to therapy. The Veridex CellSearch® System is the only semi-automated system designed to standardize and optimize the measurement of CTC in peripheral blood, this test is also the only FDA approved kit for CTC detection.